Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Curon Biopharma

Request full access

Develops innovative cancer immunotherapies, with several promising treatments in clinical stages

Huangpu, ChinaFounded 2018Biotech & Life Sciences

About Curon Biopharma

Curon Biopharma operates as a clinical-stage biopharmaceutical company with a focus on developing treatments for cancer. Founded in 2018, the company was incubated by the healthcare-focused investment firm 6 Dimensions Capital. Its establishment included a significant $150 million Series A financing round from investors such as 6 Dimensions Capital, Boyu Capital, and Temasek. Headquartered in Shanghai, China, Curon also maintains operations in Australia and Hong Kong.

The company's business model centers on the research, development, and monetization of a pipeline of immuno-oncology therapies. Revenue is generated through strategic partnerships and asset acquisitions by larger pharmaceutical companies. A notable achievement was the agreement with Merck for the global rights to Curon's lead asset, CN201. This deal involved a substantial upfront payment of $700 million, with the potential for an additional $600 million in milestone payments tied to development and regulatory approvals. Zhihong Chen serves as the company's president and CEO, with Dr. Paul H. Song appointed as Chief Scientific Officer in 2018. Dr. Song contributes over 25 years of experience in pharmaceutical research and development, including roles at Eli Lilly and Samsung Bioepis.

Curon's product pipeline features multiple candidates, including bispecific antibodies and antibody-drug conjugates. The lead candidate, CN201, is a bispecific antibody designed to target and eliminate B-cells by engaging T-cells. It works by targeting both the CD3 protein on T-cells and the CD19 protein on B-cells. This mechanism has shown potential in treating B-cell malignancies and autoimmune diseases. CN201 has been evaluated in clinical trials for conditions such as relapsed or refractory non-Hodgkin's lymphoma (NHL) and B-cell acute lymphocytic leukemia (ALL). Preliminary data from these trials indicated that the therapy was well-tolerated and showed activity in reducing B-cell populations in patients.

Source: Dealroom company data

At a glance

Status
Operational
Employees
8
Open positions
None listed
Dealroom signal
36.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jul 2018 $150M $600M Temasek · Boyu Capital · 6 Dimensions Capital —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Curon Biopharma website traffic

Latest recorded traffic for Curon Biopharma is 700 monthly website visits, up 66.7% over the last three months. Curon Biopharma's team declined 11.1% over the past year.

Latest monthly visits700 3-month web change+66.7% 1-year team growth-11.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Curon Biopharma in the Huangpu ecosystem

Live from Dealroom

The Curon Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Temasek
  • Boyu Capital
  • 6 Dimensions Capital
Employees 8 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇳 China50%
🇭🇰 Hong Kong16.7%
🇺🇸 United States16.7%
🇦🇺 Australia16.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Curon Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Curon Biopharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.